摘要
目的 通过血清学检测以探讨GST-π、sIgA和Ferr,对肝脏良恶性占位性病变鉴别诊断价值。方法血清GST-π参照本室建立的双抗体夹心ELISA法进行检测,sIgA和Ferr采用RIA法进行检测。 结果 肝癌组(n=38)血清GST-π、sIgA和Ferr含量均值分别为51.05±46.51 mg/L,52.7±31.3 mg/L和394.7±202μg/L。显著高于正常对照组(n=73)和肝良性占位性疾病组(n=24)。其阳性率分别为90.6％,85.7％和54.7％。对AFP阴性肝癌也有84.6％,81.2％和34.6％的检出率。 结论 GST-π、sIgA检测是辅以AFP对肝癌临床诊断有较大帮助的肿瘤标志物。可显著提高AFP阴性肝癌的检出率。对肝良恶性占位性疾病的鉴别诊断有很大的帮助。
AIM By the detection of serum GST- π, sIgA and ferritin(Ferr), we analysed the differentiating value of these tumor markers in patients with liver benign (n =24) and malignant (n =38) masses. METHODS Serum GST - TV was detected by the double antibody san-wich ELISA, and serum sIgA, Ferr and AFP by the radioimmunoassay.RESULTS The levels of serum GST - π, sIgA and Ferr in the primary hepatic carcinoma (PHC) were 51.05 ±46.51 mg/L, 52.7±31.3 mg/ L and 394. 7±202 μg/L respectively. Which were all significantly higher than those in normal controls and liver benign masses. The pos-itivity rates were 90.6%, 85.7% and 54.7% for the PHC and 84.6%, 82.2% and 34.6% for the PHC with negative AFP. CONCLUSION GST - π and Ferr are useful tumor markers and im-Prove the diagnosis of PHC, especially in AFP negative PHC. The detection of AFP, GST - π and Ferr is helpful to differentiate the liver malignant from benign masses.
关键词
原发性
肝癌
诊断
血清
铁蛋白
肝占位病变
primary liver cancer liver benign mass GST-π sIgA ferritin
